��ժҪ��Ϣ

[an error occurred while processing this directive]

��Ƥ��Բ�ѧ��־ 2003, 29(2) 78-81 DOI: ISSN: 2096-5540 CN: 32-1880/R

��Ŀ¼ | ��Ŀ¼ | �� | �߼�� [��ӡ��ҳ] [�ر�]

��

	��չ��

	��Ϣ
	Supporting info
	PDFȫ��
	[HTMLȫ��]
	�ο��
	��뷴��
	�ѱ��Ƽ��
	��ҵ��
	��ù��
	��ñ��
	Email Alert
	��·��
	��Ϣ
	��Ĺؼ��
	��м��
	��Ʒ�
	��
	��ʿ��
	��
	PubMed
	Article by
	Article by

��м��ƽ�չ

��ʿ��, ��

�й�Э��ҽ�ƴ�ѧ��й�ҽѧ��ѧԺƤ��о��, �Ͼ�210042

ժҪ��

��Ŷ��м��Ƶ��о�,һЩ��а�λ��Ե��Ƽ��̳��,��ȡ��˿�ϲ��Ч��жԽ��м��Ƶ��Ƽ��ֱ��ɱ��²�Tϸ��Tϸ����Ǩ�ơ��ʹ��ƫ��֢��ϸ��ӻ��4��û��ڽ��˴��Թ��,��û��ơ��ٴ��ۼ�ҩ��ѧ��

�ؼ���� м�� Ʒ�

Abstract:

Keywords:

�ո�� 2002-09-26 �޻�� ��淢��

DOI:

��Ŀ:

ͨѶ��:

��߼��:

�ο��ף�

[1] Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol, 2002, 46 (1):1-23.
[2] Martin A, Gutierrez E, Muglia J,et al. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB (389) IL-2) in patients with severe psoriasis. J Am Acad Dermatol, 2001,45 (6):871-881.
[3] da Silva AJ, Brickelmaier M, Majeau GR, et al. Al efacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2 (+) cells. J Immunol, 2002, 168(9):4462-4471.
[4] Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by sc lective targeting of memory effector T lymphocytes. N Engl J Med, 2001, 345(4):248-255.
[5] Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol, 2002, 138 (5):686-688.
[6] Branco L, Barren P, Mao SY, et al. Selective deletion of antigen-spe cific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation, 1999,68(10):1588-1596.
[7] Chau LA, Tso JY, Melrose J, et al. HuM291 (Nuvion), a humanized Fc receptor-nonbinding antibody against CD3, anergizes peripheral blood T cells as partial agonist of the T cell receptor. Transplantation, 2001, 71(7):941-950.
[8] Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease:immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11 a antibody. Arch Dermatol, 2002, 138(5):591-600.
[9] Singri P, West DP, Gordon KB. Biologic therapy for psoriasis:the new therapeutic frontier. Arch Dermatol, 2002, 138(5):657-663.
[10] Gotflieb AB, Lebwohl M, Shirin S,et al. Anti-CD4 monoclonal anti body treatment of moderate to severe psoriasis vulgaris:results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol, 2000, 43(4):595-604.
[11] Krueger JG, Walters IB, Miyasawa M, et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with pso riasis. J Am Acad Dermatol, 2000, 43(3):448-458.
[12] Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with pso riasis vulgaris. J Clin Invest, 1999, 103(9):1243-1252.
[13] Abrams JR, Kelley SL, Hayes E, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med, 2000, 192(5):681-694.
[14] Trepicchio WL, Ozawa M, Walters IB,et al. Interleukin-11 therapy selectively downregulates type �� cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest, 1999, 104 (11):1527-1537.
[15] Asadullah K, Sterry W, Stephanek K, et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy:a new therapeutic approach. J Clin Invest, 1998, 101(4):783-794.
[16] Reich K, Garbe C, Blaschke V, et al. Response of psoriasis to inter leukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 path way and normalization of keratinocyte maturation. J Invest Dermatol, 2001, 116(2):319-329.
[17] Asadullah K, Docke WD, Ebeling M,et al. Interleukin 10 treatment of psoriasis:clinical results of a phase 2 trial. Arch Dermatol, 1999, 135(2):187-192.
[18] Friedrich M, Docke WD, KleinA, et al. Immunomodulation by inter leukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis. J Invest Dermatol, 2002, 118 (4):672-677.
[19] Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis:observations on combination therapy. Br J Derma tol, 2002, 146(1):118-121.
[20] Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol, 2002,46(6):886-891.
[21] Cather J, Menter A. Novel therapies for psoriasis. Am J Clin Derma tol, 2002, 3(3):159-173.
[22] Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis:a randomised trial. Lancet, 2000, 356(9227):385-390.
[23] Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with in fliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med, 2001,345 (15):1098-1104.
[24] Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis:a randomised trial.Lancet, 2001,357(9271):1842-1847.
[25] OQuinn RP, Miller JL. The effectiveness of tumor necrosis factor al pha antibody (infliximab) in treating recalcitrant psoriasis:a report of2 cases. Arch Dermatol, 2002, 138(5):644-648.